JP2024534012A5 - - Google Patents
Info
- Publication number
- JP2024534012A5 JP2024534012A5 JP2024508641A JP2024508641A JP2024534012A5 JP 2024534012 A5 JP2024534012 A5 JP 2024534012A5 JP 2024508641 A JP2024508641 A JP 2024508641A JP 2024508641 A JP2024508641 A JP 2024508641A JP 2024534012 A5 JP2024534012 A5 JP 2024534012A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- amino acid
- product according
- pharmaceutical product
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163233048P | 2021-08-13 | 2021-08-13 | |
| US63/233,048 | 2021-08-13 | ||
| US202163242380P | 2021-09-09 | 2021-09-09 | |
| US63/242,380 | 2021-09-09 | ||
| US202263328441P | 2022-04-07 | 2022-04-07 | |
| US63/328,441 | 2022-04-07 | ||
| PCT/US2022/074897 WO2023019236A1 (en) | 2021-08-13 | 2022-08-12 | Methods for treating non-muscle invasive bladder cancer (nmibc) with antibody drug conjugates (adc) that bind to 191p4d12 proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024534012A JP2024534012A (ja) | 2024-09-18 |
| JP2024534012A5 true JP2024534012A5 (enExample) | 2025-07-30 |
Family
ID=85201025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024508641A Pending JP2024534012A (ja) | 2021-08-13 | 2022-08-12 | １９１ｐ４ｄ１２タンパク質に結合する抗体薬物複合体（ａｄｃ）を用いた非筋肉浸潤性膀胱癌（ｎｍｉｂｃ）の治療方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250135020A1 (enExample) |
| EP (1) | EP4384279A4 (enExample) |
| JP (1) | JP2024534012A (enExample) |
| KR (1) | KR20240042109A (enExample) |
| AU (1) | AU2022328339A1 (enExample) |
| CA (1) | CA3223690A1 (enExample) |
| IL (1) | IL310175A (enExample) |
| MX (1) | MX2024001834A (enExample) |
| TW (1) | TW202315612A (enExample) |
| WO (1) | WO2023019236A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202191201A1 (ru) | 2018-12-03 | 2022-01-26 | Эдженсис, Инк. | Фармацевтические композиции, включающие конъюгаты анти-191p4d12 антитело-лекарственное средство, и способы их применения |
| AU2024304180A1 (en) * | 2023-06-13 | 2026-01-08 | Adcentrx Therapeutics, Inc. | Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040081653A1 (en) * | 2002-08-16 | 2004-04-29 | Raitano Arthur B. | Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer |
| ES2874306T3 (es) * | 2010-09-29 | 2021-11-04 | Agensys Inc | Conjugados de anticuerpos y fármacos (CAF) que se unen a las proteínas 191P4D12 |
| WO2021022172A1 (en) * | 2019-08-01 | 2021-02-04 | Incyte Corporation | A dosing regimen for an ido inhibitor |
| US20230270871A1 (en) * | 2020-06-19 | 2023-08-31 | Agensys, Inc. | Markers for use in methods for treating cancers with antibody drug conjugates (adc) |
-
2022
- 2022-08-12 KR KR1020247008395A patent/KR20240042109A/ko active Pending
- 2022-08-12 JP JP2024508641A patent/JP2024534012A/ja active Pending
- 2022-08-12 TW TW111130416A patent/TW202315612A/zh unknown
- 2022-08-12 CA CA3223690A patent/CA3223690A1/en active Pending
- 2022-08-12 MX MX2024001834A patent/MX2024001834A/es unknown
- 2022-08-12 AU AU2022328339A patent/AU2022328339A1/en active Pending
- 2022-08-12 IL IL310175A patent/IL310175A/en unknown
- 2022-08-12 EP EP22856829.1A patent/EP4384279A4/en active Pending
- 2022-08-12 US US18/682,886 patent/US20250135020A1/en active Pending
- 2022-08-12 WO PCT/US2022/074897 patent/WO2023019236A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW202323296A (zh) | 組合療法 | |
| JP2023545432A5 (enExample) | ||
| BR112021008778A2 (pt) | Métodos de tratamento da oftalmopatia de graves usando anticorpos anti-fcrn | |
| WO2019096194A1 (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| JP2024133544A5 (enExample) | ||
| JP2021518394A5 (enExample) | ||
| CN114746117A (zh) | 抗dll3药剂的给药方案 | |
| JP2022513684A5 (enExample) | ||
| US20210079078A1 (en) | Compositions for Treating Amyloidosis | |
| JP2022513386A5 (enExample) | ||
| WO2023061472A1 (zh) | 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| WO2022109302A9 (en) | Anti-galectin-9 antibodies and therapeutic uses thereof | |
| US20250049940A1 (en) | Combined Use of Anti-TROP-2 Antibody-drug Conjugate and other Therapeutic Agents | |
| JP2023500697A5 (enExample) | ||
| TWI870592B (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| WO2011090005A1 (ja) | 大腸癌の治療用医薬および治療方法 | |
| CN119055767A (zh) | 包含抗her2双特异性抗体的联合治疗药物及其用途 | |
| JP2023500480A5 (enExample) | ||
| WO2021060425A1 (ja) | 全身性強皮症治療用医薬組成物 | |
| Kennedy et al. | Sequence-dependent hematological toxicity associated with the 3-hour paclitaxel/cyclophosphamide doublet. | |
| US20230049147A1 (en) | Anti-il-36r antibodies for the treatment of a fibrotic condition | |
| US20210309736A1 (en) | Use of il-1b binding antibodies for the treatment of alcoholic hepatitis | |
| US20230338496A1 (en) | Vaccination against diabetes, obesity and complications thereof | |
| US11623003B2 (en) | Vaccination against diabetes, obesity and complications thereof | |
| CN116549428B (zh) | 4-羟基异亮氨酸的新用途 |